Why the study?
What is the current evidence for the use of pharmacological therapies in patients with chronic thromboembolic pulmonary hypertension?
What is the current evidence for the use of pharmacological therapies in patients with chronic thromboembolic pulmonary hypertension?
This review highlights that while traditional PAH therapies lack compelling evidence in CTEPH, riociguat has emerged as an approved treatment for inoperable or persistent/recurrent cases.
No takes yet. Share an insight, caveat, or question.
Evidence supports riociguat in inoperable CTEPH; leaves open benefit of other PAH therapies.
Aileen Clarke (1996) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: